What type of study is this?

This is a Pre-Registered Trial study.

December 8, 2025BloodOpen Access

A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a

View Full Paper

Ask AI

Bookmark

Authors

Phase 2 trial shows high response rate and favorable safety profile for teclistamab-daratumumab in elderly with newly diagnosed multiple myeloma.

78% of patients achieved very good partial response after 4 cycles of treatment, indicating strong efficacy.
100% overall response rate reported, with 97% achieving VGPR or better, highlighting treatment effectiveness.
Open-label phase 2 trial assessed elderly patients ineligible for high-dose chemotherapy, providing new treatment insights.
Significant safety profile noted, with adverse events reported in 76% of patients, indicating need for monitoring in this population.

Macro et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Phase 2 trial shows high response rate and favorable safety profile for teclistamab-daratumumab in elderly with newly diagnosed multiple myeloma.

78% of patients achieved very good partial response after 4 cycles of treatment, indicating strong efficacy.
100% overall response rate reported, with 97% achieving VGPR or better, highlighting treatment effectiveness.
Open-label phase 2 trial assessed elderly patients ineligible for high-dose chemotherapy, providing new treatment insights.
Significant safety profile noted, with adverse events reported in 76% of patients, indicating need for monitoring in this population.

Macro et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark